Next-generation sequencing workflow for NSCLC critical samples using a targeted sequencing approach by ion torrent PGM™ platform

International Journal of Molecular Sciences

Volumn 16, Issue 12, 2015, Pages 28765-28782

  Vanni, Irene ^a   Coco, Simona ^a   Truini, Anna ^a   Rusmini, Marta ^b   Dal Bello, Maria Giovanna ^a   Alama, Angela ^a   Banelli, Barbara ^a   Mora, Marco ^a   Rijavec, Erika ^a   Barletta, Giulia ^a   Genova, Carlo ^a   Biello, Federica ^a   Maggioni, Claudia ^a   Grossi, Francesco ^a  

^a UNIVERSITY OF GENOA   (Italy)

^b G GASLINI INSTITUTE   (Italy)

Author keywords

CfDNA; FFPE; Ion Torrent PGM; Next generation sequencing; NGS workflow; NSCLC

Indexed keywords

GENOMIC DNA;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; DNA EXTRACTION; FEMALE; GENE AMPLIFICATION; HUMAN; HUMAN TISSUE; LIMIT OF DETECTION; MALE; MIDDLE AGED; MULTIPLEX POLYMERASE CHAIN REACTION; NEXT GENERATION SEQUENCING; NON SMALL CELL LUNG CANCER; PREDICTIVE VALUE; PYROSEQUENCING; QUALITY CONTROL; SENSITIVITY AND SPECIFICITY; SINGLE NUCLEOTIDE POLYMORPHISM; VERY ELDERLY; BIOLOGY; CANCER STAGING; GENETICS; HIGH THROUGHPUT SEQUENCING; LUNG TUMOR; MUTATION; PATHOLOGY; PROCEDURES; STANDARDS; WORKFLOW;

ADULT; AGED; CARCINOMA, NON-SMALL-CELL LUNG; COMPUTATIONAL BIOLOGY; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; LUNG NEOPLASMS; MIDDLE AGED; MUTATION; NEOPLASM STAGING; POLYMORPHISM, SINGLE NUCLEOTIDE; QUALITY CONTROL; SENSITIVITY AND SPECIFICITY; WORKFLOW;

EID: 84949435541     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms161226129     Document Type: Article

References (63)

1. Siegel, R.; Ma, J.; Zou, Z.; Jemal, A. Cancer statistics, 2014. CA Cancer J. Clin. 2014, 64, 9–29. [CrossRef] [PubMed]
2. Pao, W.; Miller, V.; Zakowski, M.; Doherty, J.; Politi, K.; Sarkaria, I.; Singh, B.; Heelan, R.; Rusch, V.; Fulton, L.; et al. EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc. Natl. Acad. Sci. USA 2004, 101, 13306–13311. [CrossRef] [PubMed]
3. Coco, S.; Truini, A.; Vanni, I.; dal Bello, M.G.; Alama, A.; Rijavec, E.; Genova, C.; Barletta, G.; Sini, C.; Burrafato, G.; et al. Next generation sequencing in non-small cell lung cancer: New avenues toward the personalized medicine. Curr. Drug Targets 2015, 16, 47–59. [CrossRef] [PubMed]
4. Sanger, F.; Nicklen, S.; Coulson, A.R. DNA sequencing with chain terminating inhibitors. Proc. Natl. Acad. Sci. USA 1977, 74, 5463–5467. [CrossRef] [PubMed]
5. Higuchi, R.; Fockler, C.; Dollinger, G.; Watson, R. Kinetic PCR analysis: Real-time monitoring of DNA amplification reactions. Biotechnology 1993, 11, 1026–1030. [CrossRef] [PubMed]
6. Ronaghi, M.; Uhlén, M.; Nyrén, P. A sequencing method based on real-time pyrophosphate. Science 1998, 281, 363–365. [CrossRef] [PubMed]
7. Hantson, I.; Dooms, C.; Verbeken, E.; Vandenberghe, P.; Vliegen, L.; Roskams, T.; Borght, S.V.; Nackaerts, K.; Wauters, I.; Vansteenkiste, J. Performance of standard procedures in detection of EGFR mutations in daily practice in advanced NSCLC patients selected according to the ESMO guideline: A large Caucasian cohort study. Transl. Respir. Med. 2014, 2. [CrossRef] [PubMed]
8. Cronin, M.; Ross, J.S. Comprehensive next-generation cancer genome sequencing in the era of targeted therapy and personalized oncology. Biomark. Med. 2011, 5, 293–305. [CrossRef] [PubMed]
9. Couraud, S.; Vaca-Paniagua, F.; Villar, S.; Oliver, J.; Schuster, T.; Blanché, H.; Girard, N.; Trédaniel, J.; Guilleminault, L.; Gervais, R.; et al. BioCAST/IFCT-1002 investigators: Noninvasive diagnosis of actionable mutations by deep sequencing of circulating free DNA in lung cancer from never-smokers: A proof-of-concept study from BioCAST/IFCT-1002. Clin. Cancer Res. 2014, 20, 4613–4624. [CrossRef] [PubMed]
10. Nomenclature for the description of sequence variants. Available online: http://www.hgvs.org/mutnomen/ (accessed on 10 April 2015).
11. Den Dunnen, J.T.; Antonarakis, S.E. Mutation nomenclature extensions and suggestions to describe complex mutations: A discussion. Hum. Mutat. 2000, 15, 7–12. [CrossRef]
12. Richards, S.; Aziz, N.; Bale, S.; Bick, D.; Das, S.; Gastier-Foster, J.; Grody, W.W.; Hegde, M.; Lyon, E.; Spector, E.; et al. Standards and guidelines for the interpretation of sequence variants: A joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet. Med. 2015, 17, 405–424. [CrossRef] [PubMed]
13. COSMIC (Catalogue of Somatic Mutations in Cancer). Available online: http://cancer.sanger.ac.uk/cosmic (accessed on 28 February 2015).
14. Choudhary, A.; Mambo, E.; Sanford, T.; Boedigheimer, M.; Twomey, B.; Califano, J.; Hadd, A.; Oliner, K.S.; Beaudenon, S.; Latham, G.J.; et al. Evaluation of an integrated clinical workflow for targeted next-generation sequencing of low-quality tumor DNA using a 51-gene enrichment panel. BMC Med. Genom. 2014, 7. [CrossRef] [PubMed]
15. Zhang, L.; Chen, L.; Sah, S.; Latham, G.J.; Patel, R.; Song, Q.; Koeppen, H.; Tam, R.; Schleifman, E.; Mashhedi, H.; et al. Profiling cancer gene mutations in clinical formalin-fixed, paraffin-embedded colorectal tumor specimens using targeted next-generation sequencing. Oncologist 2014, 19, 336–343. [CrossRef] [PubMed]
16. Hadd, A.G.; Houghton, J.; Choudhary, A.; Sah, S.; Chen, L.; Marko, A.C.; Sanford, T.; Buddavarapu, K.; Krosting, J.; Garmirek, L.; et al. Targeted, high-depth, next-generation sequencing of cancer genes in formalin-fixed, paraffin-embedded and fine-needle aspiration tumor specimens. J. Mol. Diagn. 2013, 15, 234–247. [CrossRef] [PubMed]
17. Hagemann, I.S.; Devarakonda, S.; Lockwood, C.M.; Spencer, D.H.; Guebert, K.; Bredemeyer, A.J.; al-Kateb, H.; Nguyen, T.T.; Duncavage, E.J.; Cottrell, C.E.; et al. Clinical next-generation sequencing in patients with non-small cell lung cancer. Cancer 2015, 121, 631–639. [CrossRef] [PubMed]
18. D’Haene, N.; le Mercier, M.; de Nève, N.; Blanchard, O.; Delaunoy, M.; el Housni, H.; Dessars, B.; Heimann, P.; Remmelink, M.; Demetter, P.; et al. Clinical Validation of Targeted Next Generation Sequencing for Colon and Lung Cancers. PLoS ONE 2015, 10, e0138245. [CrossRef] [PubMed]
19. Sah, S.; Chen, L.; Houghton, J.; Kemppainen, J.; Marko, A.C.; Zeigler, R.; Latham, G.J. Functional DNA quantification guides accurate next-generation sequencing mutation detection in formalin-fixed, paraffin-embedded tumor biopsies. Genome Med. 2013, 5, 77. [CrossRef] [PubMed]
20. Simbolo, M.; Gottardi, M.; Corbo, V.; Fassan, M.; Mafficini, A.; Malpeli, G.; Lawlor, R.T.; Scarpa, A. DNA qualification workflow for next generation sequencing of histopathological samples. PLoS ONE 2013, 8, e62692. [CrossRef] [PubMed]
21. Ross, M.G.; Russ, C.; Costello, M.; Hollinger, A.; Lennon, N.J.; Hegarty, R.; Nusbaum, C.; Jaffe, D.B. Characterizing and measuring bias in sequence data. Genome Biol. 2013, 14. [CrossRef] [PubMed]
22. Wilm, A.; Aw, P.P.; Bertrand, D.; Yeo, G.H.; Ong, S.H.; Wong, C.H.; Khor, C.C.; Petric, R.; Hibberd, M.L.; Nagarajan, N. LoFreq: A sequence quality aware, ultra-sensitive variant caller for uncovering cell population heterogeneity from high-throughput sequencing datasets. Nucleic Acids Res. 2012, 40, 11189–11201. [CrossRef] [PubMed]
23. Genome Analysis Toolkit (GATK). Available online: https://www.broadinstitute.org/gatk/index.php (accessed on 3 February 2015).
24. Boland, J.F.; Chung, C.C.; Roberson, D.; Mitchell, J.; Zhang, X.; Im, K.M.; He, J.; Chanock, S.J.; Yeager, M.; Dean, M. The new sequencer on the block: Comparison of Life Technology’s Proton sequencer to an Illumina HiSeq for whole-exome sequencing. Hum. Genet. 2013, 132, 1153–1163. [CrossRef] [PubMed]
25. Gerlinger, M.; Rowan, A.J.; Horswell, S.; Larkin, J.; Endesfelder, D.; Gronroos, E.; Martinez, P.; Matthews, N.; Stewart, A.; Tarpey, P.; et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N. Engl. J. Med. 2012, 366, 883–892. [CrossRef] [PubMed]
26. Vogelstein, B.; Papadopoulos, N.; Velculescu, V.E.; Zhou, S.; Diaz, L.A., Jr.; Kinzler, K.W. Cancer genome landscapes. Science 2013, 339, 1546–1558. [CrossRef] [PubMed]
27. Sakurada, A.; Lara-Guerra, H.; Liu, N.; Shepherd, F.A.; Tsao, M.S. Tissue heterogeneity of EGFR mutation in lung adenocarcinoma. J. Thorac. Oncol. 2008, 3, 527–529. [CrossRef] [PubMed]
28. Zhang, J.; Fujimoto, J.; Zhang, J.; Wedge, D.C.; Song, X.; Zhang, J.; Seth, S.; Chow, C.W.; Cao, Y.; Gumbs, C.; et al. Intratumor heterogeneity in localized lung adenocarcinomas delineated by multiregion sequencing. Science 2014, 346, 256–259. [CrossRef] [PubMed]
29. De Bruin, E.C.; McGranahan, N.; Mitter, R.; Salm, M.; Wedge, D.C.; Yates, L.; Jamal-Hanjani, M.; Shafi, S.; Murugaesu, N.; Rowan, A.J.; et al. Spatial and temporal diversity in genomic instability processes defines lung cancer evolution. Science 2014, 346, 251–256. [CrossRef] [PubMed]
30. Imielinski, M.; Berger, A.H.; Hammerman, P.S.; Hernandez, B.; Pugh, T.J.; Hodis, E.; Cho, J.; Suh, J.; Capelletti, M.; Sivachenko, A.; et al. Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing. Cell 2012, 150, 1107–1120. [CrossRef] [PubMed]
31. Cancer Genome Atlas Research Network. Comprehensive genomic characterization of squamous cell lung cancers. Nature 2012, 489, 519–525.
32. Zhang, X.; Miao, X.; Guo, Y.; Tan, W.; Zhou, Y.; Sun, T.; Wang, Y.; Lin, D. Genetic polymorphisms in cell cycle regulatory genes MDM2 and TP53 are associated with susceptibility to lung cancer. Hum. Mutat. 2006, 27, 110–117. [CrossRef] [PubMed]
33. Zheng, D.; Chen, Y.; Gao, C.; Wei, Y.; Cao, G.; Lu, N.; Hou, Y.; Jiang, X.; Wang, J. Polymorphisms of p53 and MDM2 genes are associated with severe toxicities in patients with non-small cell lung cancer. Cancer Biol. Ther. 2014, 15, 1542–1551. [CrossRef] [PubMed]
34. Govindan, R.; Ding, L.; Griffith, M.; Subramanian, J.; Dees, N.D.; Kanchi, K.L.; Maher, C.A.; Fulton, R.; Fulton, L.; Wallis, J.; et al. Genomic landscape of non-small cell lung cancer in smokers and never-smokers. Cell 2012, 50, 1121–1134. [CrossRef] [PubMed]
35. Diaz, L.A., Jr.; Bardelli, A. Liquid biopsies: Genotyping circulating tumor DNA. J. Clin. Oncol. 2014, 32, 579–586. [CrossRef] [PubMed]
36. Zhang, L.; Cui, X.; Schmitt, K.; Hubert, R.; Navidi, W.; Arnheim, N. Whole genome amplification from a single cell: Implications for genetic analysis. Proc. Natl. Acad. Sci. USA 1992, 89, 5847–5851. [CrossRef] [PubMed]
37. Telenius, H.; Carter, N.P.; Bebb, C.E.; Nordenskjold, M.; Ponder, B.A.; Tunnacliffe, A. Degenerate oligonucleotide-primed PCR: General amplification of target DNA by a single degenerate primer. Genomics 1992, 13, 718–725. [CrossRef]
38. Kamberov, E.; Sleptsova, I.; Suchyta, S.; Bruening, E.; Zeihler, W.; Nagel, J.S.; Langmore, J.; Makarov, V. Use of in vitro OmniPlex Libraries for high-throughput comparative genomics and molecular haplotyping. Proc. SPIE 2002, 4626, 340–351.
39. Langmore, J.P. Rubicon Genomics, Inc. Pharmacogenomics 2002, 3, 557–560. [CrossRef] [PubMed]
40. Lizardi, P.M.; Huang, X.; Zhu, Z.; Bray-Ward, P.; Thomas, D.C.; Ward, D.C. Mutation detection and single-molecule counting using isothermal rolling-circle amplification. Nat. Genet. 1998, 19, 225–232. [CrossRef] [PubMed]
41. Dean, F.B.; Hosono, S.; Fang, L.; Wu, X.; Faruqi, A.F.; Bray-Ward, P.; Sun, Z.; Zong, Q.; Du, Y.; Du, J.; et al. Comprehensive human genome amplification using multiple displacement amplification. Proc. Natl. Acad. Sci. USA 2002, 99, 5261–5266. [CrossRef] [PubMed]
42. Barker, D.L.; Hansen, M.S.; Faruqi, A.F.; Giannola, D.; Irsula, O.R.; Lasken, R.S.; Latterich, M.; Makarov, V.; Oliphant, A.; Pinter, J.H.; et al. Two methods of whole-genome amplification enable accurate genotyping across a 2320-SNP linkage panel. Genome Res. 2004, 14, 901–907. [CrossRef] [PubMed]
43. Bergen, A.W.; Haque, K.A.; Qi, Y.; Beerman, M.B.; Garcia-Closas, M.; Rothman, N.; Chanock, S.J. Comparison of yield and genotyping performance of multiple displacement amplification and OmniPlex whole genome amplified DNA generated from multiple DNA sources. Hum. Mutat. 2005, 26, 262–270. [CrossRef] [PubMed]
44. Park, J.W.; Beaty, T.H.; Boyce, P.; Scott, A.F.; McIntosh, I. Comparing whole-genome amplification methods and sources of biological samples for single-nucleotide polymorphism genotyping. Clin. Chem. 2005, 51, 1520–1523. [CrossRef] [PubMed]
45. Pask, R.; Rance, H.E.; Barratt, B.J.; Nutland, S.; Smyth, D.J.; Sebastian, M.; Twells, R.C.; Smith, A.; Lam, A.C.; Smink, L.J.; et al. Investigating the utility of combining Phi29 whole genome amplification and highly multiplexed single nucleotide polymorphism BeadArray genotyping. BMC Biotechnol. 2004, 4. [CrossRef] [PubMed]
46. Pinard, R.; deWinter, A.; Sarkis, G.J.; Gerstein, M.B.; Tartaro, K.R.; Plant, R.N.; Egholm, M.; Rothberg, J.M.; Leamon, J.H. Assessment of whole genome amplification-induced bias through high-throughput, massively parallel whole genome sequencing. BMC Genom. 2006, 7. [CrossRef] [PubMed]
47. Yilmaz, S.; Singh, A.K. Single cell genome sequencing. Curr. Opin. Biotechnol. 2011, 23, 1–7. [CrossRef] [PubMed]
48. Bergen, A.W.; Qi, Y.; Haque, K.A.; Welch, R.A.; Chanock, S.J. Effects of DNA mass on multiple displacement whole genome amplification and genotyping performance. BMC Biotechnol. 2005, 5. [CrossRef] [PubMed]
49. Hansen, H.M.; Wiemels, J.L.; Wrensch, M.; Wiencke, J.K. DNA quantification of whole genome amplified samples for genotyping on a multiplexed bead array platform. Cancer Epidemiol. Biomark. Prev. 2007, 16, 1686–1690. [CrossRef] [PubMed]
50. Paez, J.G.; Lin, M.; Beroukhim, R.; Lee, J.C.; Zhao, X.; Richter, D.J.; Gabriel, S.; Herman, P.; Sasaki, H.; Altshuler, D.; et al. Genome coverage and sequence fidelity of Phi29 polymerase-based multiple strand displacement whole genome amplification. Nucleic Acids Res. 2004, 32. [CrossRef] [PubMed]
51. Hosono, S.; Faruqi, A.F.; Dean, F.B.; Du, Y.; Sun, Z.; Wu, X.; Du, J.; Kingsmore, S.F.; Egholm, M.; Lasken, R.S. Unbiased whole-genome amplification directly from clinical samples. Genome Res. 2003, 13, 954–964. [CrossRef] [PubMed]
52. Lim, E.H.; Zhang, S.L.; Li, J.L.; Yap, W.S.; Howe, T.C.; Tan, B.P.; Lee, Y.S.; Wong, D.; Khoo, K.L.; Seto, K.Y.; et al. Using whole genome amplification (WGA) of low-volume biopsies to assess the prognostic role of EGFR, KRAS, p53, and CMET mutations in advanced-stage non-small cell lung cancer (NSCLC). J. Thorac. Oncol. 2009, 4, 12–21. [CrossRef] [PubMed]
53. Bettegowda, C.; Sausen, M.; Leary, R.J.; Kinde, I.; Wang, Y.; Agrawal, N.; Bartlett, B.R.; Wang, H.; Luber, B.; Alani, R.M.; et al. Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci. Transl. Med. 2014, 6. [CrossRef] [PubMed]
54. Diehl, F.; Schmidt, K.; Choti, M.A.; Romans, K.; Goodman, S.; Li, M.; Thornton, K.; Agrawal, N.; Sokoll, L.; Szabo, S.A.; et al. Circulating mutant DNA to assess tumor dynamics. Nat. Med. 2008, 14, 985–990. [CrossRef] [PubMed]
55. Van Beers, E.H.; Joosse, S.A.; Ligtenberg, M.J.; Fles, R.; Hogervorst, F.B.; Verhoef, S.; Nederlof, P.M. A multiplex PCR predictor for aCGH success of FFPE samples. Br. J. Cancer 2006, 94, 333–337. [CrossRef] [PubMed]
56. Thorvaldsdóttir, H.; Robinson, J.T.; Mesirov, J.P. Integrative Genomics Viewer (IGV): High-performance genomics data visualization and exploration. Brief. Bioinform. 2013, 14, 178–192. [CrossRef] [PubMed]
57. Cingolani, P.; Platts, A.; Wang, L.L.; Coon, M.; Nguyen, T.; Wang, L.; Land, S.J.; Lu, X.; Ruden, D.M. A program for annotating and predicting the effects of single nucleotide polymorphisms, SnpEff: SNPs in the genome of Drosophila melanogaster strain w1118; iso-2; iso-3. Fly 2012, 6, 80–92. [CrossRef] [PubMed]
58. PolyPhen-2 prediction of functional effects of human nsSNPs. Available online: http://genetics.bwh.harvard.edu/pph2/ (accessed on 28 February 2015).
59. SIFT Blink. Available online: http://sift.jcvi.org/ (accessed on 28 February 2015).
60. 1000Genomes. Available online: http://www.1000genomes.org/ (accessed on 28 February 2015).
61. Coco, S.; Truini, A.; Alama, A.; dal-Bello, M.G.; Venè, R.; Garuti, A.; Carminati, E.; Rijavec, E.; Genova, C.; Barletta, G.; et al. Afatinib resistance in non-small cell lung cancer involves the PI3K/AKT and MAPK/ERK signalling pathways and epithelial-to-mesenchymal transition. Target Oncol. 2015, 10, 393–404. [CrossRef] [PubMed]
62. Rehm, H.L.; Bale, S.J.; Bayrak-Toydemir, P.; Berg, J.S.; Brown, K.K.; Deignan, J.L.; Friez, J.; Funke, B.H.; Hegde, M.R.; Lyon, E.; et al. ACMG clinical laboratory standards for next-generation sequencing. Genet. Med. 2013, 15, 733–747. [CrossRef] [PubMed]
63. Coco, S.; de Mariano, M.; Valdora, F.; Servidei, T.; Ridola, V.; Andolfo, I.; Oberthuer, A.; Tonini, G.P.; Longo, L. Identification of ALK germline mutation (3605delG) in pediatric anaplastic medulloblastoma. J. Hum. Genet. 2012, 57, 682–684. [CrossRef] [PubMed]